Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Apixaban
Treatment for Atrial Fibrillation
Typical Dosage: 5 mg twice daily (or 2.5 mg twice daily for specific criteria)
Effectiveness
90%
Safety Score
65%
Clinical Trials
177
Participants
70K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
5 mg twice daily (or 2.5 mg twice daily for specific criteria)
Time to Effect
Immediate (within hours)
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
40(Treat 40 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
100(Treat 100 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$5,500
Monitoring:$150
Side Effect Mgmt:$750
Total Annual:$6,400
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$40,000/QALY
QALYs Gained
0.6
Comparison vs Warfarin
Cost Difference
+$2,000/year
More expensive
QALY Difference
+0.40 QALYs
Better outcomes
Dominance
No dominance
Apixaban Outcomes
for Atrial Fibrillation
Efficacy Outcomes
Overall Effectiveness
+90%
Common Side Effects
Minor bleeding (epistaxis, bruising)
+15%
Major bleeding (gastrointestinal, intracranial)
+2%
Gastrointestinal upset
+7%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
6 active trials recruiting for Apixaban in Atrial Fibrillation
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869ACTIVE NOT RECRUITINGPHASE3
20.3K participants
INTERVENTIONAL
Alexander City, United States +1051 more
Started: Apr 11, 2023
Efficacy and Safety of Apixaban in Korean Frail Atrial Fibrillation Patient
NCT05773222ACTIVE NOT RECRUITING
2.5K participants
OBSERVATIONAL
Seoul, South Korea
Started: Aug 12, 2019
Pharmacokinetics of Apixaban in Peritoneal Dialysis
NCT05532878RECRUITING
50 participants
OBSERVATIONAL
Shatin, Hong Kong
Started: Dec 1, 2020
COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation
NCT04642430RECRUITINGPHASE4
3.02K participants
INTERVENTIONAL
Victoria, Canada +7 more
Started: Jul 6, 2021
Comparing the Safety and Efficacy of Apixaban and Rivaroxaban
NCT06953726NOT YET RECRUITINGPHASE4
10K participants
INTERVENTIONAL
Boston, United States
Started: Jun 1, 2026
Apixaban Safety and Therapy Adherence in Patients With Atrial Fibrillation
NCT07458191RECRUITING
800 participants
OBSERVATIONAL
Sarajevo, Bosnia and Herzegovina
Started: Oct 9, 2025
Completed Clinical Trials
10 completed trials for Apixaban in Atrial Fibrillation
Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation
NCT02608099COMPLETEDPHASE4
300 participants
INTERVENTIONAL
Huntsville, United States +18 more
Started: Nov 1, 2015
Eliquis Safety Surveillance in Japanese Patients With NonValvular Atrial Fibrillation
NCT02007655COMPLETED
6.37K participants
OBSERVATIONAL
Toyama, Japan
Started: Sep 1, 2013
A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation
NCT00787150COMPLETEDPHASE2
222 participants
INTERVENTIONAL
Nagoya, Japan +17 more
Started: Jun 1, 2008
Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque
NCT02090075COMPLETEDPHASE4
66 participants
INTERVENTIONAL
Torrance, United States
Started: Sep 1, 2014
Prediction of the COBRRA AF Anticoagulant Trial in Healthcare Claims Data
NCT05256797COMPLETED
354K participants
OBSERVATIONAL
Boston, United States
Started: May 3, 2021
Eliquis Regulatory Post Marketing Surveillance
NCT01885598COMPLETED
3.33K participants
OBSERVATIONAL
Seoul, South Korea
Started: Jul 10, 2013
Replication of the ARISTOTLE Anticoagulant Trial in Healthcare Claims Data
NCT04593030COMPLETED
221K participants
OBSERVATIONAL
Boston, United States
Started: Sep 1, 2020
Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice
NCT03847181COMPLETED
45.2K participants
OBSERVATIONAL
Many Sites, United Kingdom
Started: Feb 28, 2019
Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)
NCT01884350COMPLETEDPHASE4
1.22K participants
INTERVENTIONAL
Antwerp, Belgium +219 more
Started: Oct 15, 2013
A Phase III Study of Apixaban in Patients With Atrial Fibrillation
NCT00496769COMPLETEDPHASE3
6.42K participants
INTERVENTIONAL
Mobile, United States +502 more
Started: Aug 31, 2007
Showing 20 of 185 total trials